Researchers at the NYU Grossman School of Medicine have initiated a Phase 2 clinical trial, BARCONA, evaluating Reata Pharmaceuticals’ (RETA -0.4%) bardoxolone methyl in COVID-19 patients. The primary endpoint is safety.
Bardoxolone methyl is an oral once-daily antioxidant inflammation modulator that targets the Nrf2 pathway, a regulator of antioxidant proteins that protect against oxidative damage associated with injury or inflammation.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.